FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stanley McElhinney

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Concepts & Ideas

Structure-Activity Relationship

Co-author Network

Publications

TOP 3
Malcolm Ranson; Mark R Middleton; John Bridgewater; Siow Ming Lee; Martin Dawson; Debra Jowle; Gavin Halbert; Sue Waller; Helen McGrath; Lindsey Gumbrell; R Stanley McElhinney; Dorothy J Donnelly; T Brian H McMurry; Geoffrey P Margison
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Takayuki Shibata; Nicola Glynn; T Brian H McMurry; R Stanley McElhinney; Geoffrey P Margison; David M Williams
Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT).
M Clemons; J Kelly; Amanda J Watson; A Howell; R Stanley McElhinney; T Brian H McMurry; Geoffrey P Margison
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stanley McElhinney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Malcolm Ranson; Mark R Middleton; John Bridgewater; Siow Ming Lee; Martin Dawson; Debra Jowle; Gavin Halbert; Sue Waller; Helen McGrath; Lindsey Gumbrell; R Stanley McElhinney; Dorothy J Donnelly; T Brian H McMurry; Geoffrey P Margison
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1577-84.
2006: Takayuki Shibata; Nicola Glynn; T Brian H McMurry; R Stanley McElhinney; Geoffrey P Margison; David M Williams
Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT).
Nucleic acids research 2006;34(6):1884-91.
2005: M Clemons; J Kelly; Amanda J Watson; A Howell; R Stanley McElhinney; T Brian H McMurry; Geoffrey P Margison
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
British journal of cancer 2005;93(10):1152-6.
2004: Vincent A Barvaux; Paul Lorigan; Malcolm Ranson; Amanda M Gillum; R Stanley McElhinney; T Brian H McMurry; Geoffrey P Margison
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Molecular cancer therapeutics 2004;3(10):1215-20.
2004: Vincent A Barvaux; Malcolm Ranson; Robert Brown; R Stanley McElhinney; T Brian H McMurry; Geoffrey P Margison
Dual repair modulation reverses Temozolomide resistance in vitro.
Molecular cancer therapeutics 2004;3(2):123-7.
2003: R Stanley McElhinney; T Brian H McMurry; Geoffrey P Margison
O6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy.
Mini reviews in medicinal chemistry 2003;3(5):471-85.
2002: Mark R Middleton; Nick Thatcher; T Brian H McMurry; R Stanley McElhinney; Dorothy J Donnelly; Geoffrey P Margison
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
International journal of cancer. Journal international du cancer 2002;100(5):615-7.
2000: Mark R Middleton; J Kelly; Nick Thatcher; Dorothy J Donnelly; R Stanley McElhinney; T Brian H McMurry; J E McCormick; Geoffrey P Margison
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
International journal of cancer. Journal international du cancer 2000;85(2):248-52.
1999: Michael C Bibby; M J Thompson; Joseph Rafferty; Geoffrey P Margison; R Stanley McElhinney
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.
British journal of cancer 1999;79(9-10):1332-9.
1998: R Stanley McElhinney; Dorothy J Donnelly; J E McCormick; J Kelly; Amanda J Watson; Joseph Rafferty; R H Elder; Mark R Middleton; MA Willington; T Brian H McMurry; Geoffrey P Margison
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain.
Journal of medicinal chemistry 1998;41(26):5265-71.
1996: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; M Radacic; P Dumont
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
Journal of medicinal chemistry 1996;39(7):1403-12.
1996: Paul M Loadman; A M Matthew; J E McCormick; R Stanley McElhinney; Michael C Bibby
Pharmacokinetics and anti-tumour activity of B.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogue.
Anti-cancer drug design 1996;11(2):117-28.
1993: Michael C Bibby; John A Double; J E McCormick; R Stanley McElhinney; M Radacic; G Pratesi; P Dumont
Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5-substituent and the point of attachment (N1 or N3) of the uracil moiety in seco-nucleoside nitrosoureas.
Anti-cancer drug design 1993;8(2):115-28.
1992: Paul M Loadman; Michael C Bibby; John A Double; R Stanley McElhinney
Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.
Investigational new drugs 1992;10(3):149-58.
1990: J E McCormick; R Stanley McElhinney
Nitrosoureas from chemist to physician: classification and recent approaches to drug design.
European journal of cancer (Oxford, England : 1990) 1990;26(3):207-21.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Anti-cancer drug design 1989;4(3):191-207.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Anti-cancer drug design 1989;4(1):1-20.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Anti-cancer drug design 1989;3(4):255-69.
1988: R Stanley McElhinney; J E McCormick; C M Lucey
Evolution of molecular combinations involving 5-fluorouracil.
Cancer treatment reviews 1988;15(1):73-81.
1986: John A Double; Michael C Bibby; J E McCormick; R Stanley McElhinney
Nucleoside analogues. 5. Molecular combination of anti-cancer drugs: activity of 5-fluorouracil/nitrosourea combinations against mouse colon tumours.
Anti-cancer drug design 1986;1(2):133-9.
1986: J E McCormick; R Stanley McElhinney
Nucleoside analogues. 4. Molecular combinations of anti-tumour drugs: synthesis of 5-fluorouracil seco-nucleosides with N-(2-chloroethyl)-N-nitrosourea residues by using aryl N-nitrosocarbamates.
Anti-cancer drug design 1986;1(2):111-23.